Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a new report on Creo Medical Group PLC (AIM:CREO) that follows a £33.7mln fundraise.
Appiah gives his take on what the placing means for Creo's cash position, adding that he expects the company to be cash flow positive in the "first half of 2025."